Variant Summary
- Also known as
- TPM3-NTRK1
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 8
Evidence Level Distribution
Level A: 1Level C: 5Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = TPM3::NTRK1 and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Solid Tumor | Larotrectinib Regimen | 5 |
| C | Predictive | Supports | Sensitivity/Response | Sarcoma | Larotrectinib | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Carcinoma | Larotrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Spindle Cell Sarcoma | Larotrectinib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Larotrectinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Cancer | Entrectinib | 2 |
| D | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Larotrectinib,Lestaurtinib | 2 |
| C | Predictive | Supports | Sensitivity/Response | Myofibroma | Entrectinib | 1 |